SCHEMBL22651234

SCHEMBL22651234

CCOC(=O)N(C)c1ncccc1COC(=O)CNC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ LMNA P02545 4/20 0.35
▸ MAPT P10636 3/20 0.35
▸ HTT P42858 3/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ BRD4 O60885 1/20 0.35
▸ CYP1A2 P05177 2/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ TDP2 O95551 2/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ CASP3 P42574 1/20 0.34
▸ SENP8 Q96LD8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24604442 0.91 RAB9A (0.36) RAB9AALDH1A1NPC1SMN1; SMN2ALOX15
SCHEMBL24496166 0.91 KCNH2 (0.36) RAB9AALDH1A1NPC1SMN1; SMN2LMNA
SCHEMBL23698605 0.90 HTT (0.35) RAB9AALDH1A1NPC1SMN1; SMN2LMNA
SCHEMBL23084629 0.88 CHRM2 (0.34) RAB9AALDH1A1NPC1SMN1; SMN2ALOX15
SCHEMBL22651406 0.88 ELANE (0.38) RAB9AALDH1A1NPC1SMN1; SMN2LMNA
SCHEMBL23061476 0.87 HTT (0.37) RAB9AALDH1A1NPC1SMN1; SMN2LMNA
SCHEMBL17485425 0.86 RAB9A (0.39) RAB9AALDH1A1NPC1SMN1; SMN2LMNA
SCHEMBL24604432 0.86 NPC1 (0.35) RAB9AALDH1A1NPC1SMN1; SMN2LMNA
SCHEMBL22650959 0.84 NPC1 (0.36) RAB9AALDH1A1NPC1SMN1; SMN2LMNA
SCHEMBL25657186 0.84 RAB9A (0.37) RAB9AALDH1A1NPC1SMN1; SMN2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11771688-B2 Pyridine derivatives substituted by heterocyclic ring and amino group AMPLYX PHARMACEUTICALS, INC. (US) 2023-10-03 — — US disclosed
US-20210275510-A1 PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND AMINO GROUP BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) 2021-09-09 — — US disclosed
WO-2020227337-A1 PRODRUG COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2020-11-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210275510-A1 PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND AMINO GROUP ERG28, PDXK, PAH RAB9A 1999/4885ALDH1A1 2148/4885NPC1 1336/4885
US-11771688-B2 Pyridine derivatives substituted by heterocyclic ring and amino group ERG28, PDXK, PAH RAB9A 1999/4885ALDH1A1 2148/4885NPC1 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback